2 Stocks That Could Triple Your Investment by 2030

80
5
Favorite

2 Stocks That Could Triple Your Investment by 2030

Motley Fool2023-05-05

Projecting a company's future growth is a great way to figure out which businesses can meaningfully expand over the long run and increase wealth and which ones are simply over-hyped.Let's look at a ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（5）

Sphere
·2023-05-06
LOL
Reply
2
Report
Fold Replies
- Sphere:
  Nice joke
  2023-05-06
  Reply
  Report
h20_mako
·2023-05-06
V
Reply
4
Report
小辉goPro
·2023-05-05
I will never believe [Sly]
Reply
10
Report
ADL1M
·2023-05-05
Dispend to you all supporter outside there is will buy this 2stock for coming soon future or not and all is how you looking forward to this 2news stock in market ...
Reply
9
Report
Fold Replies
- ADL1M:
  cancel direct better
  2023-05-06
  Reply
  Report
- ADL1M:
  cancel direct better
  2023-05-06
  Reply
  Report
miker9110
·2023-05-05
G
Reply
8
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2332929940?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-05-05 23:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2332929940","market":"us","top_or_hot":-1,"title":"2 Stocks That Could Triple Your Investment by 2030","media":"Motley Fool","content":"<div>\n<p>Projecting a company's future growth is a great way to figure out which businesses can meaningfully expand over the long run and increase wealth and which ones are simply over-hyped.Let's look at a ...</p>\n\n<a href=\"https://www.fool.com/investing/2023/05/03/2-stocks-that-could-triple-your-investment-by-2030/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Stocks That Could Triple Your Investment by 2030</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Stocks That Could Triple Your Investment by 2030\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-05-05 23:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2023/05/03/2-stocks-that-could-triple-your-investment-by-2030/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Projecting a company's future growth is a great way to figure out which businesses can meaningfully expand over the long run and increase wealth and which ones are simply over-hyped.Let's look at a ...</p>\n\n<a href=\"https://www.fool.com/investing/2023/05/03/2-stocks-that-could-triple-your-investment-by-2030/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNDL","symbol_name":"SNDL Inc.","start_time":0,"source_url":"https://www.fool.com/investing/2023/05/03/2-stocks-that-could-triple-your-investment-by-2030/","article_id":"2332929940","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2332929940","pubTimestamp":1683300466,"columns":[],"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"It pays to sell in-demand products and be positioned to buy out the competition.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNDL":"SNDL Inc.","NVO":"诺和诺德"},"translate_title":"到2030年，两只股票可以让你的投资翻三倍","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":0.9,"SNDL":0.9},"content_text":"Projecting a company's future growth is a great way to figure out which businesses can meaningfully expand over the long run and increase wealth and which ones are simply over-hyped.Let's look at a pair of hot growth stocks whose underlying businesses probably have what it takes to triple your investment before the close of the decade. While one of them could be a risky investment, both have credible paths to making shareholders a richer.1. Novo NordiskNovo Nordisk is a Danish pharma company that's been in the news lately, thanks to its drug semaglutide. The Food and Drug Administration (FDA) approved the drug in the U.S. for treating obesity, which sells under the trade name Wegovy. Additionally, semaglutide is also approved to treat type 2 diabetes and sold under the trade names Ozempic, an injectable, and Rybelsus, a pill.Currently, the company's investigating semaglutide for other indications as well, like Alzheimer's disease, in late-stage clinical trials. And if the fact that its obesity care segment grew by 84% in 2022 means anything at all, it's that this company has a lot of growth on the way.Over the last 10 years, Novo Nordisk grew its annual diluted earnings per share (EPS) at an average of 10.1% per year, reaching $3.59. Now, thanks largely to its anticipated semaglutide earnings, Wall Street analysts predict that, on average, its long-term EPS growth rate will be 20.7% annually. At that pace, its 2022 net income of $7.8 billion will expand to around $26.7 billion by 2030. And if its price-to-earnings (P/E) ratio remains at 44.2, its market cap could surpass $1.1 trillion -- more than triple its current value of $354 billion.So, in principle, Novo Nordisk stock could indeed triple over the next 6.5 years. But that doesn't mean you should bet the bank on it happening. Even with a portfolio of great products, growing earnings by roughly 20% per year for more than half a decade is quite difficult for a large and established business.Plus, there's always the chance that market phenomena will cause its P/E ratio to compress, meaning it would take a significantly faster pace of net income growth to still triple in value relative to today. Nonetheless, this stock isn't very risky thanks to its in-demand medicines and the likely output of its development pipeline. So don't be too afraid to buy a few shares, as a purchase will probably pay off over the coming years.2. SNDLSNDL is a Canadian cannabis and liquor business that doesn't exactly have a hit drug like semaglutide to sell. Instead, SNDL's path to tripling by 2030 involves it surviving a decidedly toxic cocktail of market and economic factors that currently appear to be harming its competitors to the point that they will be relatively easy to buy out.In a nutshell, it's a bad time to be a cannabis company. After experiencing a brutal collapse from the frothy frenzy of 2021, the market presently has shunned cannabis stocks. Most public businesses in the industry are unprofitable, and the piecemeal nature of marijuana legalization in the U.S. remains a major stumbling block.More importantly, the North American marijuana markets are being punished by companies lowering cannabis prices because of excess weed floating around compared to the level of demand. There are too many goods chasing too few consumers.But for a business like SNDL, these conditions make for the perfect setup. It currently has CA$207 million in unrestricted cash on hand and no debt. Due to significant impairments from its last set of acquisitions, it isn't profitable; however, it made CA$28.6 million in cash from operations in the fourth quarter, and its cash balance only dropped by CA$6.7 million in 2022.At the same time, as a result of some of its prior investments and lending to other U.S. marijuana companies, it could gain a majority owner of one or two of the multi-state operators (MSOs) there. That could power its top line to surpass CA$1 billion before the end of 2023, up from 2022's sum of CA$712.2 million.To triple, SNDL's market cap would need to reach approximately 1.2 billion U.S. dollars, up from its market cap near $400 million today. But right now, its price-to-sales (P/S) ratio is only 0.6, far lower than most of its competitors, not to mention the market's average P/S of 2.4. Let's assume it succeeds with its plans to gain control of a U.S. MSO or two so that by the end of 2023, it will reach CA$1 billion in sales, which is actually a bit lower than analysts' estimates.If it can then simply grow its annual revenue by a measly 8.5% annually over the six years following 2023, it'll easily triple to reach a market cap of $1.2 billion, provided its P/S expands a bit to reach a still-super-low value of 1.0. But if its valuation corrects to a level merely in the ballpark of the market's average, it could triple while growing even slower -- and with acquisition opportunities abounding, growing slower is unlikely. Still, its shares could also lose a lot of value between now and 2030, thanks to the difficult market conditions. So don't buy it unless you're brave.","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[{"id":9947549094,"gmtCreate":1683336025318,"gmtModify":1683336028196,"author":{"id":"3573432013960035","authorId":"3573432013960035","name":"Sphere","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":4,"crmLevelSwitch":0,"idStr":"3573432013960035","authorIdStr":"3573432013960035"},"htmlText":"LOL","listText":"LOL","text":"LOL","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9947549094","repostId":2332929940,"repostType":2,"repost":{"id":"2332929940","kind":"highlight","pubTimestamp":1683300466,"share":"https://ttm.financial/m/news/2332929940?lang=&edition=fundamental","pubTime":"2023-05-05 23:27","market":"us","language":"en","title":"2 Stocks That Could Triple Your Investment by 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2332929940","media":"Motley Fool","summary":"It pays to sell in-demand products and be positioned to buy out the competition.","content":"<html><head></head><body><p>Projecting a company&#39;s future growth is a great way to figure out which businesses can meaningfully expand over the long run and increase wealth and which ones are simply over-hyped.</p><p>Let&#39;s look at a pair of hot growth stocks whose underlying businesses probably have what it takes to triple your investment before the close of the decade. While one of them could be a risky investment, both have credible paths to making shareholders a richer.</p><h2>1. Novo Nordisk</h2><p><strong>Novo Nordisk</strong> is a Danish pharma company that&#39;s been in the news lately, thanks to its drug semaglutide. The Food and Drug Administration (FDA) approved the drug in the U.S. for treating obesity, which sells under the trade name Wegovy. Additionally, semaglutide is also approved to treat type 2 diabetes and sold under the trade names Ozempic, an injectable, and Rybelsus, a pill.</p><p>Currently, the company&#39;s investigating semaglutide for other indications as well, like Alzheimer&#39;s disease, in late-stage clinical trials. And if the fact that its obesity care segment grew by 84% in 2022 means anything at all, it&#39;s that this company has a lot of growth on the way.</p><p>Over the last 10 years, Novo Nordisk grew its annual diluted earnings per share (EPS) at an average of 10.1% per year, reaching $3.59. Now, thanks largely to its anticipated semaglutide earnings, Wall Street analysts predict that, on average, its long-term EPS growth rate will be 20.7% annually. At that pace, its 2022 net income of $7.8 billion will expand to around $26.7 billion by 2030. And if its price-to-earnings (P/E) ratio remains at 44.2, its market cap could surpass $1.1 trillion -- more than triple its current value of $354 billion.</p><p>So, in principle, Novo Nordisk stock could indeed triple over the next 6.5 years. But that doesn&#39;t mean you should bet the bank on it happening. Even with a portfolio of great products, growing earnings by roughly 20% per year for more than half a decade is quite difficult for a large and established business.</p><p>Plus, there&#39;s always the chance that market phenomena will cause its P/E ratio to compress, meaning it would take a significantly faster pace of net income growth to still triple in value relative to today. Nonetheless, this stock isn&#39;t very risky thanks to its in-demand medicines and the likely output of its development pipeline. So don&#39;t be too afraid to buy a few shares, as a purchase will probably pay off over the coming years.</p><h2>2. SNDL</h2><p><strong>SNDL</strong> is a Canadian cannabis and liquor business that doesn&#39;t exactly have a hit drug like semaglutide to sell. Instead, SNDL&#39;s path to tripling by 2030 involves it surviving a decidedly toxic cocktail of market and economic factors that currently appear to be harming its competitors to the point that they will be relatively easy to buy out.</p><p>In a nutshell, it&#39;s a bad time to be a cannabis company. After experiencing a brutal collapse from the frothy frenzy of 2021, the market presently has shunned cannabis stocks. Most public businesses in the industry are unprofitable, and the piecemeal nature of marijuana legalization in the U.S. remains a major stumbling block.</p><p>More importantly, the North American marijuana markets are being punished by companies lowering cannabis prices because of excess weed floating around compared to the level of demand. There are too many goods chasing too few consumers.</p><p>But for a business like SNDL, these conditions make for the perfect setup. It currently has CA$207 million in unrestricted cash on hand and no debt. Due to significant impairments from its last set of acquisitions, it isn&#39;t profitable; however, it made CA$28.6 million in cash from operations in the fourth quarter, and its cash balance only dropped by CA$6.7 million in 2022.</p><p>At the same time, as a result of some of its prior investments and lending to other U.S. marijuana companies, it could gain a majority owner of one or two of the multi-state operators (MSOs) there. That could power its top line to surpass CA$1 billion before the end of 2023, up from 2022&#39;s sum of CA$712.2 million.</p><p>To triple, SNDL&#39;s market cap would need to reach approximately 1.2 billion U.S. dollars, up from its market cap near $400 million today. But right now, its price-to-sales (P/S) ratio is only 0.6, far lower than most of its competitors, not to mention the market&#39;s average P/S of 2.4. Let&#39;s assume it succeeds with its plans to gain control of a U.S. MSO or two so that by the end of 2023, it will reach CA$1 billion in sales, which is actually a bit lower than analysts&#39; estimates.</p><p>If it can then simply grow its annual revenue by a measly 8.5% annually over the six years following 2023, it&#39;ll easily triple to reach a market cap of $1.2 billion, provided its P/S expands a bit to reach a still-super-low value of 1.0. But if its valuation corrects to a level merely in the ballpark of the market&#39;s average, it could triple while growing even slower -- and with acquisition opportunities abounding, growing slower is unlikely. Still, its shares could also lose a lot of value between now and 2030, thanks to the difficult market conditions. So don&#39;t buy it unless you&#39;re brave.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Stocks That Could Triple Your Investment by 2030</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Stocks That Could Triple Your Investment by 2030\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-05-05 23:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2023/05/03/2-stocks-that-could-triple-your-investment-by-2030/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Projecting a company's future growth is a great way to figure out which businesses can meaningfully expand over the long run and increase wealth and which ones are simply over-hyped.Let's look at a ...</p>\n\n<a href=\"https://www.fool.com/investing/2023/05/03/2-stocks-that-could-triple-your-investment-by-2030/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNDL":"SNDL Inc.","NVO":"诺和诺德"},"source_url":"https://www.fool.com/investing/2023/05/03/2-stocks-that-could-triple-your-investment-by-2030/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2332929940","content_text":"Projecting a company's future growth is a great way to figure out which businesses can meaningfully expand over the long run and increase wealth and which ones are simply over-hyped.Let's look at a pair of hot growth stocks whose underlying businesses probably have what it takes to triple your investment before the close of the decade. While one of them could be a risky investment, both have credible paths to making shareholders a richer.1. Novo NordiskNovo Nordisk is a Danish pharma company that's been in the news lately, thanks to its drug semaglutide. The Food and Drug Administration (FDA) approved the drug in the U.S. for treating obesity, which sells under the trade name Wegovy. Additionally, semaglutide is also approved to treat type 2 diabetes and sold under the trade names Ozempic, an injectable, and Rybelsus, a pill.Currently, the company's investigating semaglutide for other indications as well, like Alzheimer's disease, in late-stage clinical trials. And if the fact that its obesity care segment grew by 84% in 2022 means anything at all, it's that this company has a lot of growth on the way.Over the last 10 years, Novo Nordisk grew its annual diluted earnings per share (EPS) at an average of 10.1% per year, reaching $3.59. Now, thanks largely to its anticipated semaglutide earnings, Wall Street analysts predict that, on average, its long-term EPS growth rate will be 20.7% annually. At that pace, its 2022 net income of $7.8 billion will expand to around $26.7 billion by 2030. And if its price-to-earnings (P/E) ratio remains at 44.2, its market cap could surpass $1.1 trillion -- more than triple its current value of $354 billion.So, in principle, Novo Nordisk stock could indeed triple over the next 6.5 years. But that doesn't mean you should bet the bank on it happening. Even with a portfolio of great products, growing earnings by roughly 20% per year for more than half a decade is quite difficult for a large and established business.Plus, there's always the chance that market phenomena will cause its P/E ratio to compress, meaning it would take a significantly faster pace of net income growth to still triple in value relative to today. Nonetheless, this stock isn't very risky thanks to its in-demand medicines and the likely output of its development pipeline. So don't be too afraid to buy a few shares, as a purchase will probably pay off over the coming years.2. SNDLSNDL is a Canadian cannabis and liquor business that doesn't exactly have a hit drug like semaglutide to sell. Instead, SNDL's path to tripling by 2030 involves it surviving a decidedly toxic cocktail of market and economic factors that currently appear to be harming its competitors to the point that they will be relatively easy to buy out.In a nutshell, it's a bad time to be a cannabis company. After experiencing a brutal collapse from the frothy frenzy of 2021, the market presently has shunned cannabis stocks. Most public businesses in the industry are unprofitable, and the piecemeal nature of marijuana legalization in the U.S. remains a major stumbling block.More importantly, the North American marijuana markets are being punished by companies lowering cannabis prices because of excess weed floating around compared to the level of demand. There are too many goods chasing too few consumers.But for a business like SNDL, these conditions make for the perfect setup. It currently has CA$207 million in unrestricted cash on hand and no debt. Due to significant impairments from its last set of acquisitions, it isn't profitable; however, it made CA$28.6 million in cash from operations in the fourth quarter, and its cash balance only dropped by CA$6.7 million in 2022.At the same time, as a result of some of its prior investments and lending to other U.S. marijuana companies, it could gain a majority owner of one or two of the multi-state operators (MSOs) there. That could power its top line to surpass CA$1 billion before the end of 2023, up from 2022's sum of CA$712.2 million.To triple, SNDL's market cap would need to reach approximately 1.2 billion U.S. dollars, up from its market cap near $400 million today. But right now, its price-to-sales (P/S) ratio is only 0.6, far lower than most of its competitors, not to mention the market's average P/S of 2.4. Let's assume it succeeds with its plans to gain control of a U.S. MSO or two so that by the end of 2023, it will reach CA$1 billion in sales, which is actually a bit lower than analysts' estimates.If it can then simply grow its annual revenue by a measly 8.5% annually over the six years following 2023, it'll easily triple to reach a market cap of $1.2 billion, provided its P/S expands a bit to reach a still-super-low value of 1.0. But if its valuation corrects to a level merely in the ballpark of the market's average, it could triple while growing even slower -- and with acquisition opportunities abounding, growing slower is unlikely. Still, its shares could also lose a lot of value between now and 2030, thanks to the difficult market conditions. So don't buy it unless you're brave.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":106347741,"gmtCreate":1683336035642,"gmtModify":1683336042090,"authorId":3573432013960035,"author":{"id":3573432013960035,"idStr":"3573432013960035","authorId":3573432013960035,"name":"Sphere","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9947549094,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">Nice joke<span class=\"Apple-converted-space\"> </span></span>","text":"<span class=\"s1\">Nice joke<span class=\"Apple-converted-space\"> </span></span>","html":"<span class=\"s1\">Nice joke<span class=\"Apple-converted-space\"> </span></span>"}],"langContent":"EN"},{"id":9947554269,"gmtCreate":1683332507952,"gmtModify":1683332511707,"author":{"id":"3585385530619181","authorId":"3585385530619181","name":"h20_mako","avatar":"https://static.tigerbbs.com/815dd8430435288774e9be0c03637f83","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3585385530619181","authorIdStr":"3585385530619181"},"htmlText":"V","listText":"V","text":"V","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9947554269","repostId":2332929940,"repostType":2,"repost":{"id":"2332929940","kind":"highlight","pubTimestamp":1683300466,"share":"https://ttm.financial/m/news/2332929940?lang=&edition=fundamental","pubTime":"2023-05-05 23:27","market":"us","language":"en","title":"2 Stocks That Could Triple Your Investment by 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2332929940","media":"Motley Fool","summary":"It pays to sell in-demand products and be positioned to buy out the competition.","content":"<html><head></head><body><p>Projecting a company&#39;s future growth is a great way to figure out which businesses can meaningfully expand over the long run and increase wealth and which ones are simply over-hyped.</p><p>Let&#39;s look at a pair of hot growth stocks whose underlying businesses probably have what it takes to triple your investment before the close of the decade. While one of them could be a risky investment, both have credible paths to making shareholders a richer.</p><h2>1. Novo Nordisk</h2><p><strong>Novo Nordisk</strong> is a Danish pharma company that&#39;s been in the news lately, thanks to its drug semaglutide. The Food and Drug Administration (FDA) approved the drug in the U.S. for treating obesity, which sells under the trade name Wegovy. Additionally, semaglutide is also approved to treat type 2 diabetes and sold under the trade names Ozempic, an injectable, and Rybelsus, a pill.</p><p>Currently, the company&#39;s investigating semaglutide for other indications as well, like Alzheimer&#39;s disease, in late-stage clinical trials. And if the fact that its obesity care segment grew by 84% in 2022 means anything at all, it&#39;s that this company has a lot of growth on the way.</p><p>Over the last 10 years, Novo Nordisk grew its annual diluted earnings per share (EPS) at an average of 10.1% per year, reaching $3.59. Now, thanks largely to its anticipated semaglutide earnings, Wall Street analysts predict that, on average, its long-term EPS growth rate will be 20.7% annually. At that pace, its 2022 net income of $7.8 billion will expand to around $26.7 billion by 2030. And if its price-to-earnings (P/E) ratio remains at 44.2, its market cap could surpass $1.1 trillion -- more than triple its current value of $354 billion.</p><p>So, in principle, Novo Nordisk stock could indeed triple over the next 6.5 years. But that doesn&#39;t mean you should bet the bank on it happening. Even with a portfolio of great products, growing earnings by roughly 20% per year for more than half a decade is quite difficult for a large and established business.</p><p>Plus, there&#39;s always the chance that market phenomena will cause its P/E ratio to compress, meaning it would take a significantly faster pace of net income growth to still triple in value relative to today. Nonetheless, this stock isn&#39;t very risky thanks to its in-demand medicines and the likely output of its development pipeline. So don&#39;t be too afraid to buy a few shares, as a purchase will probably pay off over the coming years.</p><h2>2. SNDL</h2><p><strong>SNDL</strong> is a Canadian cannabis and liquor business that doesn&#39;t exactly have a hit drug like semaglutide to sell. Instead, SNDL&#39;s path to tripling by 2030 involves it surviving a decidedly toxic cocktail of market and economic factors that currently appear to be harming its competitors to the point that they will be relatively easy to buy out.</p><p>In a nutshell, it&#39;s a bad time to be a cannabis company. After experiencing a brutal collapse from the frothy frenzy of 2021, the market presently has shunned cannabis stocks. Most public businesses in the industry are unprofitable, and the piecemeal nature of marijuana legalization in the U.S. remains a major stumbling block.</p><p>More importantly, the North American marijuana markets are being punished by companies lowering cannabis prices because of excess weed floating around compared to the level of demand. There are too many goods chasing too few consumers.</p><p>But for a business like SNDL, these conditions make for the perfect setup. It currently has CA$207 million in unrestricted cash on hand and no debt. Due to significant impairments from its last set of acquisitions, it isn&#39;t profitable; however, it made CA$28.6 million in cash from operations in the fourth quarter, and its cash balance only dropped by CA$6.7 million in 2022.</p><p>At the same time, as a result of some of its prior investments and lending to other U.S. marijuana companies, it could gain a majority owner of one or two of the multi-state operators (MSOs) there. That could power its top line to surpass CA$1 billion before the end of 2023, up from 2022&#39;s sum of CA$712.2 million.</p><p>To triple, SNDL&#39;s market cap would need to reach approximately 1.2 billion U.S. dollars, up from its market cap near $400 million today. But right now, its price-to-sales (P/S) ratio is only 0.6, far lower than most of its competitors, not to mention the market&#39;s average P/S of 2.4. Let&#39;s assume it succeeds with its plans to gain control of a U.S. MSO or two so that by the end of 2023, it will reach CA$1 billion in sales, which is actually a bit lower than analysts&#39; estimates.</p><p>If it can then simply grow its annual revenue by a measly 8.5% annually over the six years following 2023, it&#39;ll easily triple to reach a market cap of $1.2 billion, provided its P/S expands a bit to reach a still-super-low value of 1.0. But if its valuation corrects to a level merely in the ballpark of the market&#39;s average, it could triple while growing even slower -- and with acquisition opportunities abounding, growing slower is unlikely. Still, its shares could also lose a lot of value between now and 2030, thanks to the difficult market conditions. So don&#39;t buy it unless you&#39;re brave.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Stocks That Could Triple Your Investment by 2030</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Stocks That Could Triple Your Investment by 2030\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-05-05 23:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2023/05/03/2-stocks-that-could-triple-your-investment-by-2030/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Projecting a company's future growth is a great way to figure out which businesses can meaningfully expand over the long run and increase wealth and which ones are simply over-hyped.Let's look at a ...</p>\n\n<a href=\"https://www.fool.com/investing/2023/05/03/2-stocks-that-could-triple-your-investment-by-2030/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNDL":"SNDL Inc.","NVO":"诺和诺德"},"source_url":"https://www.fool.com/investing/2023/05/03/2-stocks-that-could-triple-your-investment-by-2030/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2332929940","content_text":"Projecting a company's future growth is a great way to figure out which businesses can meaningfully expand over the long run and increase wealth and which ones are simply over-hyped.Let's look at a pair of hot growth stocks whose underlying businesses probably have what it takes to triple your investment before the close of the decade. While one of them could be a risky investment, both have credible paths to making shareholders a richer.1. Novo NordiskNovo Nordisk is a Danish pharma company that's been in the news lately, thanks to its drug semaglutide. The Food and Drug Administration (FDA) approved the drug in the U.S. for treating obesity, which sells under the trade name Wegovy. Additionally, semaglutide is also approved to treat type 2 diabetes and sold under the trade names Ozempic, an injectable, and Rybelsus, a pill.Currently, the company's investigating semaglutide for other indications as well, like Alzheimer's disease, in late-stage clinical trials. And if the fact that its obesity care segment grew by 84% in 2022 means anything at all, it's that this company has a lot of growth on the way.Over the last 10 years, Novo Nordisk grew its annual diluted earnings per share (EPS) at an average of 10.1% per year, reaching $3.59. Now, thanks largely to its anticipated semaglutide earnings, Wall Street analysts predict that, on average, its long-term EPS growth rate will be 20.7% annually. At that pace, its 2022 net income of $7.8 billion will expand to around $26.7 billion by 2030. And if its price-to-earnings (P/E) ratio remains at 44.2, its market cap could surpass $1.1 trillion -- more than triple its current value of $354 billion.So, in principle, Novo Nordisk stock could indeed triple over the next 6.5 years. But that doesn't mean you should bet the bank on it happening. Even with a portfolio of great products, growing earnings by roughly 20% per year for more than half a decade is quite difficult for a large and established business.Plus, there's always the chance that market phenomena will cause its P/E ratio to compress, meaning it would take a significantly faster pace of net income growth to still triple in value relative to today. Nonetheless, this stock isn't very risky thanks to its in-demand medicines and the likely output of its development pipeline. So don't be too afraid to buy a few shares, as a purchase will probably pay off over the coming years.2. SNDLSNDL is a Canadian cannabis and liquor business that doesn't exactly have a hit drug like semaglutide to sell. Instead, SNDL's path to tripling by 2030 involves it surviving a decidedly toxic cocktail of market and economic factors that currently appear to be harming its competitors to the point that they will be relatively easy to buy out.In a nutshell, it's a bad time to be a cannabis company. After experiencing a brutal collapse from the frothy frenzy of 2021, the market presently has shunned cannabis stocks. Most public businesses in the industry are unprofitable, and the piecemeal nature of marijuana legalization in the U.S. remains a major stumbling block.More importantly, the North American marijuana markets are being punished by companies lowering cannabis prices because of excess weed floating around compared to the level of demand. There are too many goods chasing too few consumers.But for a business like SNDL, these conditions make for the perfect setup. It currently has CA$207 million in unrestricted cash on hand and no debt. Due to significant impairments from its last set of acquisitions, it isn't profitable; however, it made CA$28.6 million in cash from operations in the fourth quarter, and its cash balance only dropped by CA$6.7 million in 2022.At the same time, as a result of some of its prior investments and lending to other U.S. marijuana companies, it could gain a majority owner of one or two of the multi-state operators (MSOs) there. That could power its top line to surpass CA$1 billion before the end of 2023, up from 2022's sum of CA$712.2 million.To triple, SNDL's market cap would need to reach approximately 1.2 billion U.S. dollars, up from its market cap near $400 million today. But right now, its price-to-sales (P/S) ratio is only 0.6, far lower than most of its competitors, not to mention the market's average P/S of 2.4. Let's assume it succeeds with its plans to gain control of a U.S. MSO or two so that by the end of 2023, it will reach CA$1 billion in sales, which is actually a bit lower than analysts' estimates.If it can then simply grow its annual revenue by a measly 8.5% annually over the six years following 2023, it'll easily triple to reach a market cap of $1.2 billion, provided its P/S expands a bit to reach a still-super-low value of 1.0. But if its valuation corrects to a level merely in the ballpark of the market's average, it could triple while growing even slower -- and with acquisition opportunities abounding, growing slower is unlikely. Still, its shares could also lose a lot of value between now and 2030, thanks to the difficult market conditions. So don't buy it unless you're brave.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9947566884,"gmtCreate":1683300512749,"gmtModify":1683300516739,"author":{"id":"3582372814286152","authorId":"3582372814286152","name":"小辉goPro","avatar":"https://community-static.tradeup.com/news/92dffa198c36919245944c656eb0dd7d","vip":1,"crmLevel":2,"crmLevelSwitch":1,"idStr":"3582372814286152","authorIdStr":"3582372814286152"},"htmlText":"I will never believe&nbsp;[Sly]&nbsp;","listText":"I will never believe&nbsp;[Sly]&nbsp;","text":"I will never believe [Sly]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9947566884","repostId":2332929940,"repostType":2,"repost":{"id":"2332929940","kind":"highlight","pubTimestamp":1683300466,"share":"https://ttm.financial/m/news/2332929940?lang=&edition=fundamental","pubTime":"2023-05-05 23:27","market":"us","language":"en","title":"2 Stocks That Could Triple Your Investment by 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2332929940","media":"Motley Fool","summary":"It pays to sell in-demand products and be positioned to buy out the competition.","content":"<html><head></head><body><p>Projecting a company&#39;s future growth is a great way to figure out which businesses can meaningfully expand over the long run and increase wealth and which ones are simply over-hyped.</p><p>Let&#39;s look at a pair of hot growth stocks whose underlying businesses probably have what it takes to triple your investment before the close of the decade. While one of them could be a risky investment, both have credible paths to making shareholders a richer.</p><h2>1. Novo Nordisk</h2><p><strong>Novo Nordisk</strong> is a Danish pharma company that&#39;s been in the news lately, thanks to its drug semaglutide. The Food and Drug Administration (FDA) approved the drug in the U.S. for treating obesity, which sells under the trade name Wegovy. Additionally, semaglutide is also approved to treat type 2 diabetes and sold under the trade names Ozempic, an injectable, and Rybelsus, a pill.</p><p>Currently, the company&#39;s investigating semaglutide for other indications as well, like Alzheimer&#39;s disease, in late-stage clinical trials. And if the fact that its obesity care segment grew by 84% in 2022 means anything at all, it&#39;s that this company has a lot of growth on the way.</p><p>Over the last 10 years, Novo Nordisk grew its annual diluted earnings per share (EPS) at an average of 10.1% per year, reaching $3.59. Now, thanks largely to its anticipated semaglutide earnings, Wall Street analysts predict that, on average, its long-term EPS growth rate will be 20.7% annually. At that pace, its 2022 net income of $7.8 billion will expand to around $26.7 billion by 2030. And if its price-to-earnings (P/E) ratio remains at 44.2, its market cap could surpass $1.1 trillion -- more than triple its current value of $354 billion.</p><p>So, in principle, Novo Nordisk stock could indeed triple over the next 6.5 years. But that doesn&#39;t mean you should bet the bank on it happening. Even with a portfolio of great products, growing earnings by roughly 20% per year for more than half a decade is quite difficult for a large and established business.</p><p>Plus, there&#39;s always the chance that market phenomena will cause its P/E ratio to compress, meaning it would take a significantly faster pace of net income growth to still triple in value relative to today. Nonetheless, this stock isn&#39;t very risky thanks to its in-demand medicines and the likely output of its development pipeline. So don&#39;t be too afraid to buy a few shares, as a purchase will probably pay off over the coming years.</p><h2>2. SNDL</h2><p><strong>SNDL</strong> is a Canadian cannabis and liquor business that doesn&#39;t exactly have a hit drug like semaglutide to sell. Instead, SNDL&#39;s path to tripling by 2030 involves it surviving a decidedly toxic cocktail of market and economic factors that currently appear to be harming its competitors to the point that they will be relatively easy to buy out.</p><p>In a nutshell, it&#39;s a bad time to be a cannabis company. After experiencing a brutal collapse from the frothy frenzy of 2021, the market presently has shunned cannabis stocks. Most public businesses in the industry are unprofitable, and the piecemeal nature of marijuana legalization in the U.S. remains a major stumbling block.</p><p>More importantly, the North American marijuana markets are being punished by companies lowering cannabis prices because of excess weed floating around compared to the level of demand. There are too many goods chasing too few consumers.</p><p>But for a business like SNDL, these conditions make for the perfect setup. It currently has CA$207 million in unrestricted cash on hand and no debt. Due to significant impairments from its last set of acquisitions, it isn&#39;t profitable; however, it made CA$28.6 million in cash from operations in the fourth quarter, and its cash balance only dropped by CA$6.7 million in 2022.</p><p>At the same time, as a result of some of its prior investments and lending to other U.S. marijuana companies, it could gain a majority owner of one or two of the multi-state operators (MSOs) there. That could power its top line to surpass CA$1 billion before the end of 2023, up from 2022&#39;s sum of CA$712.2 million.</p><p>To triple, SNDL&#39;s market cap would need to reach approximately 1.2 billion U.S. dollars, up from its market cap near $400 million today. But right now, its price-to-sales (P/S) ratio is only 0.6, far lower than most of its competitors, not to mention the market&#39;s average P/S of 2.4. Let&#39;s assume it succeeds with its plans to gain control of a U.S. MSO or two so that by the end of 2023, it will reach CA$1 billion in sales, which is actually a bit lower than analysts&#39; estimates.</p><p>If it can then simply grow its annual revenue by a measly 8.5% annually over the six years following 2023, it&#39;ll easily triple to reach a market cap of $1.2 billion, provided its P/S expands a bit to reach a still-super-low value of 1.0. But if its valuation corrects to a level merely in the ballpark of the market&#39;s average, it could triple while growing even slower -- and with acquisition opportunities abounding, growing slower is unlikely. Still, its shares could also lose a lot of value between now and 2030, thanks to the difficult market conditions. So don&#39;t buy it unless you&#39;re brave.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Stocks That Could Triple Your Investment by 2030</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Stocks That Could Triple Your Investment by 2030\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-05-05 23:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2023/05/03/2-stocks-that-could-triple-your-investment-by-2030/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Projecting a company's future growth is a great way to figure out which businesses can meaningfully expand over the long run and increase wealth and which ones are simply over-hyped.Let's look at a ...</p>\n\n<a href=\"https://www.fool.com/investing/2023/05/03/2-stocks-that-could-triple-your-investment-by-2030/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNDL":"SNDL Inc.","NVO":"诺和诺德"},"source_url":"https://www.fool.com/investing/2023/05/03/2-stocks-that-could-triple-your-investment-by-2030/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2332929940","content_text":"Projecting a company's future growth is a great way to figure out which businesses can meaningfully expand over the long run and increase wealth and which ones are simply over-hyped.Let's look at a pair of hot growth stocks whose underlying businesses probably have what it takes to triple your investment before the close of the decade. While one of them could be a risky investment, both have credible paths to making shareholders a richer.1. Novo NordiskNovo Nordisk is a Danish pharma company that's been in the news lately, thanks to its drug semaglutide. The Food and Drug Administration (FDA) approved the drug in the U.S. for treating obesity, which sells under the trade name Wegovy. Additionally, semaglutide is also approved to treat type 2 diabetes and sold under the trade names Ozempic, an injectable, and Rybelsus, a pill.Currently, the company's investigating semaglutide for other indications as well, like Alzheimer's disease, in late-stage clinical trials. And if the fact that its obesity care segment grew by 84% in 2022 means anything at all, it's that this company has a lot of growth on the way.Over the last 10 years, Novo Nordisk grew its annual diluted earnings per share (EPS) at an average of 10.1% per year, reaching $3.59. Now, thanks largely to its anticipated semaglutide earnings, Wall Street analysts predict that, on average, its long-term EPS growth rate will be 20.7% annually. At that pace, its 2022 net income of $7.8 billion will expand to around $26.7 billion by 2030. And if its price-to-earnings (P/E) ratio remains at 44.2, its market cap could surpass $1.1 trillion -- more than triple its current value of $354 billion.So, in principle, Novo Nordisk stock could indeed triple over the next 6.5 years. But that doesn't mean you should bet the bank on it happening. Even with a portfolio of great products, growing earnings by roughly 20% per year for more than half a decade is quite difficult for a large and established business.Plus, there's always the chance that market phenomena will cause its P/E ratio to compress, meaning it would take a significantly faster pace of net income growth to still triple in value relative to today. Nonetheless, this stock isn't very risky thanks to its in-demand medicines and the likely output of its development pipeline. So don't be too afraid to buy a few shares, as a purchase will probably pay off over the coming years.2. SNDLSNDL is a Canadian cannabis and liquor business that doesn't exactly have a hit drug like semaglutide to sell. Instead, SNDL's path to tripling by 2030 involves it surviving a decidedly toxic cocktail of market and economic factors that currently appear to be harming its competitors to the point that they will be relatively easy to buy out.In a nutshell, it's a bad time to be a cannabis company. After experiencing a brutal collapse from the frothy frenzy of 2021, the market presently has shunned cannabis stocks. Most public businesses in the industry are unprofitable, and the piecemeal nature of marijuana legalization in the U.S. remains a major stumbling block.More importantly, the North American marijuana markets are being punished by companies lowering cannabis prices because of excess weed floating around compared to the level of demand. There are too many goods chasing too few consumers.But for a business like SNDL, these conditions make for the perfect setup. It currently has CA$207 million in unrestricted cash on hand and no debt. Due to significant impairments from its last set of acquisitions, it isn't profitable; however, it made CA$28.6 million in cash from operations in the fourth quarter, and its cash balance only dropped by CA$6.7 million in 2022.At the same time, as a result of some of its prior investments and lending to other U.S. marijuana companies, it could gain a majority owner of one or two of the multi-state operators (MSOs) there. That could power its top line to surpass CA$1 billion before the end of 2023, up from 2022's sum of CA$712.2 million.To triple, SNDL's market cap would need to reach approximately 1.2 billion U.S. dollars, up from its market cap near $400 million today. But right now, its price-to-sales (P/S) ratio is only 0.6, far lower than most of its competitors, not to mention the market's average P/S of 2.4. Let's assume it succeeds with its plans to gain control of a U.S. MSO or two so that by the end of 2023, it will reach CA$1 billion in sales, which is actually a bit lower than analysts' estimates.If it can then simply grow its annual revenue by a measly 8.5% annually over the six years following 2023, it'll easily triple to reach a market cap of $1.2 billion, provided its P/S expands a bit to reach a still-super-low value of 1.0. But if its valuation corrects to a level merely in the ballpark of the market's average, it could triple while growing even slower -- and with acquisition opportunities abounding, growing slower is unlikely. Still, its shares could also lose a lot of value between now and 2030, thanks to the difficult market conditions. So don't buy it unless you're brave.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9947561346,"gmtCreate":1683299382185,"gmtModify":1683299387003,"author":{"id":"4142771666207662","authorId":"4142771666207662","name":"ADL1M","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":1,"idStr":"4142771666207662","authorIdStr":"4142771666207662"},"htmlText":"Dispend to you all supporter outside there is will buy this 2stock for coming soon future or not and all is how you looking forward to this 2news stock in market ...","listText":"Dispend to you all supporter outside there is will buy this 2stock for coming soon future or not and all is how you looking forward to this 2news stock in market ...","text":"Dispend to you all supporter outside there is will buy this 2stock for coming soon future or not and all is how you looking forward to this 2news stock in market ...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/9947561346","repostId":2332929940,"repostType":2,"repost":{"id":"2332929940","kind":"highlight","pubTimestamp":1683300466,"share":"https://ttm.financial/m/news/2332929940?lang=&edition=fundamental","pubTime":"2023-05-05 23:27","market":"us","language":"en","title":"2 Stocks That Could Triple Your Investment by 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2332929940","media":"Motley Fool","summary":"It pays to sell in-demand products and be positioned to buy out the competition.","content":"<html><head></head><body><p>Projecting a company&#39;s future growth is a great way to figure out which businesses can meaningfully expand over the long run and increase wealth and which ones are simply over-hyped.</p><p>Let&#39;s look at a pair of hot growth stocks whose underlying businesses probably have what it takes to triple your investment before the close of the decade. While one of them could be a risky investment, both have credible paths to making shareholders a richer.</p><h2>1. Novo Nordisk</h2><p><strong>Novo Nordisk</strong> is a Danish pharma company that&#39;s been in the news lately, thanks to its drug semaglutide. The Food and Drug Administration (FDA) approved the drug in the U.S. for treating obesity, which sells under the trade name Wegovy. Additionally, semaglutide is also approved to treat type 2 diabetes and sold under the trade names Ozempic, an injectable, and Rybelsus, a pill.</p><p>Currently, the company&#39;s investigating semaglutide for other indications as well, like Alzheimer&#39;s disease, in late-stage clinical trials. And if the fact that its obesity care segment grew by 84% in 2022 means anything at all, it&#39;s that this company has a lot of growth on the way.</p><p>Over the last 10 years, Novo Nordisk grew its annual diluted earnings per share (EPS) at an average of 10.1% per year, reaching $3.59. Now, thanks largely to its anticipated semaglutide earnings, Wall Street analysts predict that, on average, its long-term EPS growth rate will be 20.7% annually. At that pace, its 2022 net income of $7.8 billion will expand to around $26.7 billion by 2030. And if its price-to-earnings (P/E) ratio remains at 44.2, its market cap could surpass $1.1 trillion -- more than triple its current value of $354 billion.</p><p>So, in principle, Novo Nordisk stock could indeed triple over the next 6.5 years. But that doesn&#39;t mean you should bet the bank on it happening. Even with a portfolio of great products, growing earnings by roughly 20% per year for more than half a decade is quite difficult for a large and established business.</p><p>Plus, there&#39;s always the chance that market phenomena will cause its P/E ratio to compress, meaning it would take a significantly faster pace of net income growth to still triple in value relative to today. Nonetheless, this stock isn&#39;t very risky thanks to its in-demand medicines and the likely output of its development pipeline. So don&#39;t be too afraid to buy a few shares, as a purchase will probably pay off over the coming years.</p><h2>2. SNDL</h2><p><strong>SNDL</strong> is a Canadian cannabis and liquor business that doesn&#39;t exactly have a hit drug like semaglutide to sell. Instead, SNDL&#39;s path to tripling by 2030 involves it surviving a decidedly toxic cocktail of market and economic factors that currently appear to be harming its competitors to the point that they will be relatively easy to buy out.</p><p>In a nutshell, it&#39;s a bad time to be a cannabis company. After experiencing a brutal collapse from the frothy frenzy of 2021, the market presently has shunned cannabis stocks. Most public businesses in the industry are unprofitable, and the piecemeal nature of marijuana legalization in the U.S. remains a major stumbling block.</p><p>More importantly, the North American marijuana markets are being punished by companies lowering cannabis prices because of excess weed floating around compared to the level of demand. There are too many goods chasing too few consumers.</p><p>But for a business like SNDL, these conditions make for the perfect setup. It currently has CA$207 million in unrestricted cash on hand and no debt. Due to significant impairments from its last set of acquisitions, it isn&#39;t profitable; however, it made CA$28.6 million in cash from operations in the fourth quarter, and its cash balance only dropped by CA$6.7 million in 2022.</p><p>At the same time, as a result of some of its prior investments and lending to other U.S. marijuana companies, it could gain a majority owner of one or two of the multi-state operators (MSOs) there. That could power its top line to surpass CA$1 billion before the end of 2023, up from 2022&#39;s sum of CA$712.2 million.</p><p>To triple, SNDL&#39;s market cap would need to reach approximately 1.2 billion U.S. dollars, up from its market cap near $400 million today. But right now, its price-to-sales (P/S) ratio is only 0.6, far lower than most of its competitors, not to mention the market&#39;s average P/S of 2.4. Let&#39;s assume it succeeds with its plans to gain control of a U.S. MSO or two so that by the end of 2023, it will reach CA$1 billion in sales, which is actually a bit lower than analysts&#39; estimates.</p><p>If it can then simply grow its annual revenue by a measly 8.5% annually over the six years following 2023, it&#39;ll easily triple to reach a market cap of $1.2 billion, provided its P/S expands a bit to reach a still-super-low value of 1.0. But if its valuation corrects to a level merely in the ballpark of the market&#39;s average, it could triple while growing even slower -- and with acquisition opportunities abounding, growing slower is unlikely. Still, its shares could also lose a lot of value between now and 2030, thanks to the difficult market conditions. So don&#39;t buy it unless you&#39;re brave.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Stocks That Could Triple Your Investment by 2030</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Stocks That Could Triple Your Investment by 2030\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-05-05 23:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2023/05/03/2-stocks-that-could-triple-your-investment-by-2030/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Projecting a company's future growth is a great way to figure out which businesses can meaningfully expand over the long run and increase wealth and which ones are simply over-hyped.Let's look at a ...</p>\n\n<a href=\"https://www.fool.com/investing/2023/05/03/2-stocks-that-could-triple-your-investment-by-2030/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNDL":"SNDL Inc.","NVO":"诺和诺德"},"source_url":"https://www.fool.com/investing/2023/05/03/2-stocks-that-could-triple-your-investment-by-2030/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2332929940","content_text":"Projecting a company's future growth is a great way to figure out which businesses can meaningfully expand over the long run and increase wealth and which ones are simply over-hyped.Let's look at a pair of hot growth stocks whose underlying businesses probably have what it takes to triple your investment before the close of the decade. While one of them could be a risky investment, both have credible paths to making shareholders a richer.1. Novo NordiskNovo Nordisk is a Danish pharma company that's been in the news lately, thanks to its drug semaglutide. The Food and Drug Administration (FDA) approved the drug in the U.S. for treating obesity, which sells under the trade name Wegovy. Additionally, semaglutide is also approved to treat type 2 diabetes and sold under the trade names Ozempic, an injectable, and Rybelsus, a pill.Currently, the company's investigating semaglutide for other indications as well, like Alzheimer's disease, in late-stage clinical trials. And if the fact that its obesity care segment grew by 84% in 2022 means anything at all, it's that this company has a lot of growth on the way.Over the last 10 years, Novo Nordisk grew its annual diluted earnings per share (EPS) at an average of 10.1% per year, reaching $3.59. Now, thanks largely to its anticipated semaglutide earnings, Wall Street analysts predict that, on average, its long-term EPS growth rate will be 20.7% annually. At that pace, its 2022 net income of $7.8 billion will expand to around $26.7 billion by 2030. And if its price-to-earnings (P/E) ratio remains at 44.2, its market cap could surpass $1.1 trillion -- more than triple its current value of $354 billion.So, in principle, Novo Nordisk stock could indeed triple over the next 6.5 years. But that doesn't mean you should bet the bank on it happening. Even with a portfolio of great products, growing earnings by roughly 20% per year for more than half a decade is quite difficult for a large and established business.Plus, there's always the chance that market phenomena will cause its P/E ratio to compress, meaning it would take a significantly faster pace of net income growth to still triple in value relative to today. Nonetheless, this stock isn't very risky thanks to its in-demand medicines and the likely output of its development pipeline. So don't be too afraid to buy a few shares, as a purchase will probably pay off over the coming years.2. SNDLSNDL is a Canadian cannabis and liquor business that doesn't exactly have a hit drug like semaglutide to sell. Instead, SNDL's path to tripling by 2030 involves it surviving a decidedly toxic cocktail of market and economic factors that currently appear to be harming its competitors to the point that they will be relatively easy to buy out.In a nutshell, it's a bad time to be a cannabis company. After experiencing a brutal collapse from the frothy frenzy of 2021, the market presently has shunned cannabis stocks. Most public businesses in the industry are unprofitable, and the piecemeal nature of marijuana legalization in the U.S. remains a major stumbling block.More importantly, the North American marijuana markets are being punished by companies lowering cannabis prices because of excess weed floating around compared to the level of demand. There are too many goods chasing too few consumers.But for a business like SNDL, these conditions make for the perfect setup. It currently has CA$207 million in unrestricted cash on hand and no debt. Due to significant impairments from its last set of acquisitions, it isn't profitable; however, it made CA$28.6 million in cash from operations in the fourth quarter, and its cash balance only dropped by CA$6.7 million in 2022.At the same time, as a result of some of its prior investments and lending to other U.S. marijuana companies, it could gain a majority owner of one or two of the multi-state operators (MSOs) there. That could power its top line to surpass CA$1 billion before the end of 2023, up from 2022's sum of CA$712.2 million.To triple, SNDL's market cap would need to reach approximately 1.2 billion U.S. dollars, up from its market cap near $400 million today. But right now, its price-to-sales (P/S) ratio is only 0.6, far lower than most of its competitors, not to mention the market's average P/S of 2.4. Let's assume it succeeds with its plans to gain control of a U.S. MSO or two so that by the end of 2023, it will reach CA$1 billion in sales, which is actually a bit lower than analysts' estimates.If it can then simply grow its annual revenue by a measly 8.5% annually over the six years following 2023, it'll easily triple to reach a market cap of $1.2 billion, provided its P/S expands a bit to reach a still-super-low value of 1.0. But if its valuation corrects to a level merely in the ballpark of the market's average, it could triple while growing even slower -- and with acquisition opportunities abounding, growing slower is unlikely. Still, its shares could also lose a lot of value between now and 2030, thanks to the difficult market conditions. So don't buy it unless you're brave.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":106347547,"gmtCreate":1683329011100,"gmtModify":1683337866591,"authorId":4142771666207662,"author":{"id":4142771666207662,"idStr":"4142771666207662","authorId":4142771666207662,"name":"ADL1M","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9947561346,"type":1,"supId":0,"prevId":0,"content":"cancel direct better","text":"cancel direct better","html":"cancel direct better"},{"id":106347545,"gmtCreate":1683328967357,"gmtModify":1683337866572,"authorId":4142771666207662,"author":{"id":4142771666207662,"idStr":"4142771666207662","authorId":4142771666207662,"name":"ADL1M","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9947561346,"type":1,"supId":0,"prevId":0,"content":"cancel direct better","text":"cancel direct better","html":"cancel direct better"}],"langContent":"EN"},{"id":9947563107,"gmtCreate":1683299066509,"gmtModify":1683299069963,"author":{"id":"3568440341211251","authorId":"3568440341211251","name":"miker9110","avatar":"https://static.tigerbbs.com/74c64fa1d597623853f21e898b7d0c13","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3568440341211251","authorIdStr":"3568440341211251"},"htmlText":"G","listText":"G","text":"G","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9947563107","repostId":2332929940,"repostType":4,"repost":{"id":"2332929940","kind":"highlight","pubTimestamp":1683300466,"share":"https://ttm.financial/m/news/2332929940?lang=&edition=fundamental","pubTime":"2023-05-05 23:27","market":"us","language":"en","title":"2 Stocks That Could Triple Your Investment by 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2332929940","media":"Motley Fool","summary":"It pays to sell in-demand products and be positioned to buy out the competition.","content":"<html><head></head><body><p>Projecting a company&#39;s future growth is a great way to figure out which businesses can meaningfully expand over the long run and increase wealth and which ones are simply over-hyped.</p><p>Let&#39;s look at a pair of hot growth stocks whose underlying businesses probably have what it takes to triple your investment before the close of the decade. While one of them could be a risky investment, both have credible paths to making shareholders a richer.</p><h2>1. Novo Nordisk</h2><p><strong>Novo Nordisk</strong> is a Danish pharma company that&#39;s been in the news lately, thanks to its drug semaglutide. The Food and Drug Administration (FDA) approved the drug in the U.S. for treating obesity, which sells under the trade name Wegovy. Additionally, semaglutide is also approved to treat type 2 diabetes and sold under the trade names Ozempic, an injectable, and Rybelsus, a pill.</p><p>Currently, the company&#39;s investigating semaglutide for other indications as well, like Alzheimer&#39;s disease, in late-stage clinical trials. And if the fact that its obesity care segment grew by 84% in 2022 means anything at all, it&#39;s that this company has a lot of growth on the way.</p><p>Over the last 10 years, Novo Nordisk grew its annual diluted earnings per share (EPS) at an average of 10.1% per year, reaching $3.59. Now, thanks largely to its anticipated semaglutide earnings, Wall Street analysts predict that, on average, its long-term EPS growth rate will be 20.7% annually. At that pace, its 2022 net income of $7.8 billion will expand to around $26.7 billion by 2030. And if its price-to-earnings (P/E) ratio remains at 44.2, its market cap could surpass $1.1 trillion -- more than triple its current value of $354 billion.</p><p>So, in principle, Novo Nordisk stock could indeed triple over the next 6.5 years. But that doesn&#39;t mean you should bet the bank on it happening. Even with a portfolio of great products, growing earnings by roughly 20% per year for more than half a decade is quite difficult for a large and established business.</p><p>Plus, there&#39;s always the chance that market phenomena will cause its P/E ratio to compress, meaning it would take a significantly faster pace of net income growth to still triple in value relative to today. Nonetheless, this stock isn&#39;t very risky thanks to its in-demand medicines and the likely output of its development pipeline. So don&#39;t be too afraid to buy a few shares, as a purchase will probably pay off over the coming years.</p><h2>2. SNDL</h2><p><strong>SNDL</strong> is a Canadian cannabis and liquor business that doesn&#39;t exactly have a hit drug like semaglutide to sell. Instead, SNDL&#39;s path to tripling by 2030 involves it surviving a decidedly toxic cocktail of market and economic factors that currently appear to be harming its competitors to the point that they will be relatively easy to buy out.</p><p>In a nutshell, it&#39;s a bad time to be a cannabis company. After experiencing a brutal collapse from the frothy frenzy of 2021, the market presently has shunned cannabis stocks. Most public businesses in the industry are unprofitable, and the piecemeal nature of marijuana legalization in the U.S. remains a major stumbling block.</p><p>More importantly, the North American marijuana markets are being punished by companies lowering cannabis prices because of excess weed floating around compared to the level of demand. There are too many goods chasing too few consumers.</p><p>But for a business like SNDL, these conditions make for the perfect setup. It currently has CA$207 million in unrestricted cash on hand and no debt. Due to significant impairments from its last set of acquisitions, it isn&#39;t profitable; however, it made CA$28.6 million in cash from operations in the fourth quarter, and its cash balance only dropped by CA$6.7 million in 2022.</p><p>At the same time, as a result of some of its prior investments and lending to other U.S. marijuana companies, it could gain a majority owner of one or two of the multi-state operators (MSOs) there. That could power its top line to surpass CA$1 billion before the end of 2023, up from 2022&#39;s sum of CA$712.2 million.</p><p>To triple, SNDL&#39;s market cap would need to reach approximately 1.2 billion U.S. dollars, up from its market cap near $400 million today. But right now, its price-to-sales (P/S) ratio is only 0.6, far lower than most of its competitors, not to mention the market&#39;s average P/S of 2.4. Let&#39;s assume it succeeds with its plans to gain control of a U.S. MSO or two so that by the end of 2023, it will reach CA$1 billion in sales, which is actually a bit lower than analysts&#39; estimates.</p><p>If it can then simply grow its annual revenue by a measly 8.5% annually over the six years following 2023, it&#39;ll easily triple to reach a market cap of $1.2 billion, provided its P/S expands a bit to reach a still-super-low value of 1.0. But if its valuation corrects to a level merely in the ballpark of the market&#39;s average, it could triple while growing even slower -- and with acquisition opportunities abounding, growing slower is unlikely. Still, its shares could also lose a lot of value between now and 2030, thanks to the difficult market conditions. So don&#39;t buy it unless you&#39;re brave.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Stocks That Could Triple Your Investment by 2030</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Stocks That Could Triple Your Investment by 2030\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-05-05 23:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2023/05/03/2-stocks-that-could-triple-your-investment-by-2030/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Projecting a company's future growth is a great way to figure out which businesses can meaningfully expand over the long run and increase wealth and which ones are simply over-hyped.Let's look at a ...</p>\n\n<a href=\"https://www.fool.com/investing/2023/05/03/2-stocks-that-could-triple-your-investment-by-2030/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNDL":"SNDL Inc.","NVO":"诺和诺德"},"source_url":"https://www.fool.com/investing/2023/05/03/2-stocks-that-could-triple-your-investment-by-2030/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2332929940","content_text":"Projecting a company's future growth is a great way to figure out which businesses can meaningfully expand over the long run and increase wealth and which ones are simply over-hyped.Let's look at a pair of hot growth stocks whose underlying businesses probably have what it takes to triple your investment before the close of the decade. While one of them could be a risky investment, both have credible paths to making shareholders a richer.1. Novo NordiskNovo Nordisk is a Danish pharma company that's been in the news lately, thanks to its drug semaglutide. The Food and Drug Administration (FDA) approved the drug in the U.S. for treating obesity, which sells under the trade name Wegovy. Additionally, semaglutide is also approved to treat type 2 diabetes and sold under the trade names Ozempic, an injectable, and Rybelsus, a pill.Currently, the company's investigating semaglutide for other indications as well, like Alzheimer's disease, in late-stage clinical trials. And if the fact that its obesity care segment grew by 84% in 2022 means anything at all, it's that this company has a lot of growth on the way.Over the last 10 years, Novo Nordisk grew its annual diluted earnings per share (EPS) at an average of 10.1% per year, reaching $3.59. Now, thanks largely to its anticipated semaglutide earnings, Wall Street analysts predict that, on average, its long-term EPS growth rate will be 20.7% annually. At that pace, its 2022 net income of $7.8 billion will expand to around $26.7 billion by 2030. And if its price-to-earnings (P/E) ratio remains at 44.2, its market cap could surpass $1.1 trillion -- more than triple its current value of $354 billion.So, in principle, Novo Nordisk stock could indeed triple over the next 6.5 years. But that doesn't mean you should bet the bank on it happening. Even with a portfolio of great products, growing earnings by roughly 20% per year for more than half a decade is quite difficult for a large and established business.Plus, there's always the chance that market phenomena will cause its P/E ratio to compress, meaning it would take a significantly faster pace of net income growth to still triple in value relative to today. Nonetheless, this stock isn't very risky thanks to its in-demand medicines and the likely output of its development pipeline. So don't be too afraid to buy a few shares, as a purchase will probably pay off over the coming years.2. SNDLSNDL is a Canadian cannabis and liquor business that doesn't exactly have a hit drug like semaglutide to sell. Instead, SNDL's path to tripling by 2030 involves it surviving a decidedly toxic cocktail of market and economic factors that currently appear to be harming its competitors to the point that they will be relatively easy to buy out.In a nutshell, it's a bad time to be a cannabis company. After experiencing a brutal collapse from the frothy frenzy of 2021, the market presently has shunned cannabis stocks. Most public businesses in the industry are unprofitable, and the piecemeal nature of marijuana legalization in the U.S. remains a major stumbling block.More importantly, the North American marijuana markets are being punished by companies lowering cannabis prices because of excess weed floating around compared to the level of demand. There are too many goods chasing too few consumers.But for a business like SNDL, these conditions make for the perfect setup. It currently has CA$207 million in unrestricted cash on hand and no debt. Due to significant impairments from its last set of acquisitions, it isn't profitable; however, it made CA$28.6 million in cash from operations in the fourth quarter, and its cash balance only dropped by CA$6.7 million in 2022.At the same time, as a result of some of its prior investments and lending to other U.S. marijuana companies, it could gain a majority owner of one or two of the multi-state operators (MSOs) there. That could power its top line to surpass CA$1 billion before the end of 2023, up from 2022's sum of CA$712.2 million.To triple, SNDL's market cap would need to reach approximately 1.2 billion U.S. dollars, up from its market cap near $400 million today. But right now, its price-to-sales (P/S) ratio is only 0.6, far lower than most of its competitors, not to mention the market's average P/S of 2.4. Let's assume it succeeds with its plans to gain control of a U.S. MSO or two so that by the end of 2023, it will reach CA$1 billion in sales, which is actually a bit lower than analysts' estimates.If it can then simply grow its annual revenue by a measly 8.5% annually over the six years following 2023, it'll easily triple to reach a market cap of $1.2 billion, provided its P/S expands a bit to reach a still-super-low value of 1.0. But if its valuation corrects to a level merely in the ballpark of the market's average, it could triple while growing even slower -- and with acquisition opportunities abounding, growing slower is unlikely. Still, its shares could also lose a lot of value between now and 2030, thanks to the difficult market conditions. So don't buy it unless you're brave.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":80,"commentSize":5,"repostSize":5,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}